* To evaluate the effect of combination therapy with HIVIG (administered every 28 days until delivery beginning between 20-30 weeks of pregnancy and to the newborn within 12 hours of birth), and ZDV (administered intrapartum and to the newborn for 6 weeks), compared to IVIG and ZDV, administered similarly, on the transmissin of HIV infection to infants born to HIV-infected women. All women in this study are receiving ZDV for medical indications. * To evaluate maternal virologic and immunologic factors involved in HIV transmission from mother to infants, and the influence of HIVIG on the parameters.
Showing the most recent 10 out of 563 publications